Background {#Sec1}
==========

Oral Squamous Cell Carcinoma (OSCC) as the most frequently diagnosed cancer in the head and neck region is a very important world-wide health problem \[[@CR1]\]. About 90 % of all malignant tumours localised in the oral cavity and oropharynx are squamous cell carcinomas (SCC). Mortality for oral cancer is high because the early phase of the disease is often asymptomatic and most patients seek care with the late-stage symptoms \[[@CR2]\]. Tobacco and alcohol are well-established risk factors for OSCC. Oncogenic viruses have also been involved in OSCC development \[[@CR1], [@CR3]--[@CR8]\]. The International Agency for Research on Cancer (IARC) concluded that there is an evidence for a role of human papillomavirus (HPV), in particular HPV16, in the oropharyngeal cancer \[[@CR9], [@CR10]\]. A number of studies also suggest the role of Epstein-Barr virus (EBV) in the development of cancer in this region \[[@CR11]--[@CR14]\]. Many studies indicate that genetic mutations caused by oncogenic viruses lead to a different rates of tumour disease development. This effect is due to the varying levels of cytokines and other growth factors. These disorders lead to a faster (or slower) tumour growth as well as metastasis formation \[[@CR15]\].

It has been shown that inflammation plays a key role in different stages of carcinogenesis. Cytokines are a group of host immune products involved in inflammation, immunity and defence against HPV infection, and modulation of HPV clearance plays an important role in oncogenesis \[[@CR16]\]. Of particular interest has been the use of the salivary cytokine concentration as a marker of cell proliferation. The most studied cytokines include interleukin 10 (IL-10), tumour necrosis factor-alpha (TNF-α), vascular endothelial growth factor (VEGF) and tumour growth factor-beta (TGF-β). These salivary biomarkers were demonstrated to be increased in patients with oral cancer and several of them are still candidates for future clinical use \[[@CR16]--[@CR18]\]. Saliva is a body fluid very useful for the early diagnosis, monitoring and treatment of diseases \[[@CR18]\]. Therefore, the aim of this study was to analyze the serum and salivary levels of IL-10, TNF-α, TGF-β and VEGF in patients with oropharyngeal cancer compared to healthy individuals. We also analyzed the level of these biomarkers in HPV- and EBV-related cases.

This research was approved by the Ethics Committee and is in accordance with the GCP regulations (no. KE-0254/133/2013).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study was conducted among 78 patients with diagnosed and histopathologically confirmed OSCC hospitalized at the Otolaryngology Division of the Hospital in Radom, Poland. The patients had neither previous radiotherapy nor chemotherapy. The results were compared to 40 healthy controls. The control group involved persons hospitalized at the Otolaryngology Division due to diseases other than cancer. There were no statistically significant differences between the patients and the control group (age, sex, tobacco and alcohol consumption) (Table [1](#Tab1){ref-type="table"}). Male patients dominated in the examined group (91.03 %). The patients' ages ranged from 40 to 79 years. Most of the patients were aged 50--69 years (43.6 %), 15.4 % were under 50 years of age. Most studied individuals (64.1 %) lived in urban areas. A total of 79.5 % of the studied patients reported smoking, while 43.6 % pointed to alcohol abuse.Table 1Demographic and virological characteristics of patients and controlsPatientsControls*P* value*N*%*N*%Sexfemale78.9757.5\>0.05male7191.033592.5Age40--491215.4717.5\>0.0550--693443.61947.570 +3241.01435.0Place of residenceurban5064.12665.0\>0.05rural2835.91435.0Smokingyes6279.53280.0\>0.05no1620.5820.0Alcoholyes3443.62050.0\>0.05no4456.42050.0EBV DNApositive4051.3820.0\<0.001\*negative3747.43280.0HPV DNApositive2430.812.5\<0.001\*negative5469.23997.5\*statistically significant

DNA extraction from fresh frozen tumour tissue {#Sec4}
----------------------------------------------

Fragments of fresh frozen tumour tissue (20 mg) both from the patients with OSCC and from the control subjects were cut and homogenized in a manual homogenizer Omni TH/Omni International/ Kennesewa/ Georgia /USA. DNA was extracted using a protocol as described in the DNeasy Tissue Kit Handbook (Qiagen GmBH, Hilden, Germany). Purified DNA was quantified by spectrophotometer (Epoch Microplate Spectrophotometer, BioTek Instruments Inc., Vinooski, Vermont, USA). The isolates were kept at −20 °C until the test was conducted. To verify the quality of the obtained DNA (presence of inhibitors of Polymerase Chain Reaction), assay of β-globin was performed.

Serum collection {#Sec5}
----------------

Venous blood samples from patients and control group were centrifuged at 1500 rpm for 15 min at room temperature and the serum was collected and frozen at −80 °C until analysis.

Saliva collection {#Sec6}
-----------------

About 5 ml of unstimulated whole saliva was collected. The saliva samples were centrifuged at 1500 rpm at room temperature for 10 min and diluted (1:1) in PBS and frozen at -80 °C until analysis.

Detection of viruses {#Sec7}
--------------------

EBV DNA detection: All polymerase chain reaction (PCR) reactions were carried out in the final volume of 25 μl using HotStartTaq DNA Polymerase (Qiagen, Germany). Concentrations of PCR reaction components were prepared as follows: 2.0 mM MgCl~2~, 0.2 mM dNTPs, 0.5 μM each forward and reverse primers and 0.5 U of HotStart Taq polymerase. During each run the samples were tested together with one negative (nuclease-free water) and one positive control (EBV-positive cell line, Namalwa, ATCC-CRL-1432).

Amplification of EBNA-2 gene: The nested PCR was carried out for amplification of Epstein-Barr nuclear antigen 2 (EBNA-2). The sequence of primers used for PCR was as follows: outer pair 5' -- TTT CAC CAA TAC ATG ACC C -- 3', 5' -- TGG CAA AGT GCT GAG AGC AA -- 3' and inner pair 5' -- CAA TAC ATG AAC CRG AGT CC -- 3', 5' -- AAG TGC TGA GAG CAA GGC MC -- 3'. 2 μl of extracted DNA was subjected to the PCR mixture with the concentration as described above. The first-round amplification consisted of activation of polymerase 95 °C for 15 min, 35 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 2 min and the final extension at 72 °C for 5 min. The second-round amplification was performed with 1 μl of first round PCR product in 30 cycles with an annealing temperature at 60 °C. The amplicons 368 bp, 473 bp in length (depending on the EBV type EBV-1 and EBV-2, respectively) were separated on 2 % agarose gel and purified using Gel-Out kit (A&A Biotechnology, Poland) for further analysis. Purified PCR products were sent to Genomed Warsaw company for sequencing.

HPV DNA detection: HPV detection and genotyping was performed using the INNO-LiPA HPV Genotyping Extraassay (Innogenetics N. V, Gent, Belgium; no cat. 81063) according to the manufacturer's protocol. The kit is based on the amplification of a 65 bp fragment from the L1 region of the HPV genome. PCR products are subsequently typed with the reverse hybridization assay. The assay covers all currently known high-risk HPV genotypes and probable high-risk HPV genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as well as a number of low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).

Measuring of cytokines level {#Sec9}
----------------------------

The levels of IL-10, TNF-α, TGF-β and VEGF were established in the saliva and sera of patients and healthy subjects by ELISA (enzyme-linked immunosorbent assay) using commercially available kits Diaclone SAS, France. The cytokine level of each serum sample was tested three times and the results are the means of these. The level of tested cytokines are expressed in pg/ml or ng/ml. The minimum detectable dose of IL-10 is less than 0.98 pg/ml (IL-10 HS ELISA kit) cat. no. 850.880.096; TNF-α -- less than 8 pg/ml cat. no 950.090.096; TGF-β -- 8.6 pg/ml cat. no. 650.010.096 and VEGF -- 7.9 pg/ml cat. no. 650.080.096.

Statistical analysis {#Sec10}
--------------------

To examine differences between the patients and controls in the distributions of demographic variables, smoking and drinking status, HPV and EBV status Pearson's chi-square test was used. The Mann-Whitney test was used to compare the concentration of cytokines in patients and controls. The Kruksal-Wallis test was used to determine the association of the concentration of studied cytokines with such variables as smoking, alcohol abuse, histological grade (G) of the tumour, tumour (T) and node (N) stage according to TNM (tumour, node, metastasis) classification and presence of viruses. The observed differences were considered statistically significant at *p* \<0.05.

Results {#Sec11}
=======

The prevalence of HPV and EBV was higher in patients than in controls (*p* \< 0.001). HPV DNA was detected in 30.8 % of patients, EBV DNA in 51.3 %, while in control group in 2.5 % and 20.0 %, respectively. Epidemiological, clinical and virological characteristics of patients are shown in Table [2](#Tab2){ref-type="table"}. The level of all tested cytokines and growth factors was higher in patients than in controls both in serum and in saliva. The concentration of these biomarkers in the patients group was higher in saliva than in serum (Table [3](#Tab3){ref-type="table"}). The level of IL-10 was statistically higher in smoking patients, in patients infected with EBV, HPV as well as in EBV-HPV co-infection (Table [4](#Tab4){ref-type="table"}).Table 2Epidemiological, clinical and virological characteristics of patients (%)EBV*P* valueHPV*P* valuePositive *N* = 40Negative *N* = 38Positive *N* = 24Negative *N* = 54Sexfemale2.515.80.0401\*4.211.10.2908male97.584.295.888.9Age40--4920.010.50.4902022.20.569250--6940.047.475.029.670 +40.042.125.048.2Place of residenceurban70.057.90.265275.059.30.1736rural30.042.125.040.7Smokingyes80.078.90.908383.377.80.5692no20.021.116.722.2Alcoholyes45.042.10.796633.348.20.2196no55.057.966.757.8Histological grading G120.031.60.491133.322.80.0023\*275.063.255.077.835.05.216.70T stage110.015.80.0908018.50.0004\*245.042.175.029.7330.010.58.325.9415.031.616.725.9N stageN050.063.20.704358.355.60.7948N120.015.816.718.5N215.010.516.711.1N315.010.58.314.8\*statistically significantTable 3Serum and salivary level of cytokines in patients and controlsPatientsControls*P* valueSerumIL-10 (pg/ml)2.3 (1.2--3.9)1.65 (0.54--2.9)0.0003^a^TGF-β (ng/ml)11.3 (3.5--164.1)7.8 (1.8--26.2)0.0005^a^VEGF (pg/ml614 (14--1374)210 (17--712)0.0004^a^TNF-α (ng/ml)15.9 (4.9--39.1)12.9 (10.4--19.5)0.1397SalivaIL-10 (pg/ml)5.9 (2.9--12.7)2.5 (0.45--5.1)0.00002^a^TGF-β (ng/ml)24.1 (7--87.9)14.8 (5.4--30.1)0.00002^a^VEGF (pg/ml)4321 (1566--7791)280 (130--980)0.0000^a^TNF-α (ng/ml)23.1 (15.8--26.0)11.3 (8.2--17.7)0.00002^a^median, test U Manna Whitney'a^a^statistically significantTable 4Association of cytokines and growth factors levels with clinicopathological featuresIL-10TNF-αVEGFTGF-βSmoking0.0017^\*^0.15420.46520.9853Alcohol0.13250.09150.14330.3278Histological grade G0.11050.0344^\*^0.0421^\*^0.7569T stage0.86360.0412^\*^0.0005^\*^0.2400N stage0.25920.32300.28780.0062^\*^EBV0.0002^\*^0.0456^\*^0.05020.2842HPV0.0382^\*^0.73480.90160.0396^\*^HPV + EBV0.0331^\*^0.64160.11800.0117^\*\*^Statistically significant

There was a relationship between the concentration of both TNF-α and VEGF and the histological grade of the tumour (G) and the size of tumour (T stage), while TGF-β level was related to N stage. The level of the TNF-α was higher in patients infected with EBV, whereas TGF-β was higher in HPV and HPV/EBV co-infected patients. IL-10 concentration was higher in HPV, EBV as well as in HPV/EBV co-infected patients.

Discussion {#Sec12}
==========

Various cytokines and growth factors play a significant role both in inflammation and carcinogenesis. Some cytokines are considered as pro-inflammatory (TNF-α, IFN-ɣ), whereas other are associated with anti-inflammatory effects (TGF-β) \[[@CR2]\]. To the best of our knowledge, IL-10, TGF-β1, TNF-α and VEGF levels in patients infected with HPV and/or EBV have not been studied in the Polish population with oropharyngeal cancer.

Interleukin-10 (cytokine synthesis inhibitor factor, CSIF) is an important cytokine produced by several cells such as normal and neoplastic B cells, macrophages, T cells and some cancer cells \[[@CR19], [@CR20]\]. The immunosuppressive effects of IL-10 in the tumour environment have been repeatedly confirmed \[[@CR21]\]. Our study demonstrated higher levels of IL-10 in saliva and serum samples of patients with OSCC than in control subjects. Moreover, IL-10 concentration in saliva was higher than in serum. Goncalves et al. \[[@CR22]\] detected high expression of IL-10 in the tumour samples and elevated levels of this cytokine in saliva of patients with OSCC, which enabled to distinguish patients with cancer from healthy individuals. Jiang et al. \[[@CR23]\] additionally studied correlation between IL-10 and advancing cancer lesions on animal models. In their research higher concentrations of IL-10 were associated with more severe disease and poorer prognosis of cancer. Lathers \[[@CR24]\] observed an increase in the level of IL-10 with the formation of metastases in the lymph nodes. The influence of IL-10 on more severe cancer disease is explained by antagonistic effect of IL-10 on the formation of pro-inflammatory cytokines (IL-6, TNF, IL-1α, IL-1β, IL-12) and inhibition of the inflammatory response, which plays an important role in the development of cancer.

Tumour necrosis factor α (TNF-α) is a cytokine involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. TNF-α is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial lipopolysaccharides \[[@CR25]\]. It has a wide spectrum of biological activities including antitumour and antiviral activity. TNF-α may be involved in carcinogenesis through induction of proliferation, invasion, and metastasis because it may have both tumour-necrotic and tumour-promoting activities \[[@CR26]\]. In our study a significantly higher level of this cytokine was obtained in the patients' saliva comparing with the control group. In subjects with OSCC, TNF-α levels were higher in saliva than in serum. It may indicate the activity of the protein in close proximity to the tumour. Krishnan et al. \[[@CR27]\] obtained significantly higher levels of TNF-α both in saliva and in the blood of the patients with OSCC. In a study carried out by Juretic et al. \[[@CR28]\] salivary concentration of TNF-α was higher both in patients with premalignant oral lesions and in patients with OSCC as compared with healthy individuals. Rhodus \[[@CR29]\], on the basis of his research analyzing the concentration of TNF-α in saliva, suggests that this cytokine can be used as a prognostic parameter for cancer.

TGF-β is a cytokine involved in various biological processes. The TGF-β pathway regulates many of the cellular processes and alterations in the signalling cascade may promote tumour development. The anti-proliferative activity of TGF-β1 is essential for maintaining normal tissue homeostasis and this activity of TGF-β1 is lost in many types of tumours \[[@CR30], [@CR31]\]. Some researchers point to an increase of TGF-β concentration in the case of tumour growth and they emphasize the prognostic features of this protein \[[@CR32]\]. Other studies show no difference between the concentration of TGF-β in tissue samples and saliva \[[@CR23]\]. These differences may come from the multiple effects of this cytokine on immune cells, the formation of blood vessels and fluctuation depending on the stage of cancer. Our study demonstrated significantly higher levels of TGF-β both in saliva and in serum of patients with OSCC. Moreover, salivary level was higher than serum concentration of this cytokine in the group of patients.

Because angiogenesis is essential for the growth and metastasis of tumours, we also investigated serum and salivary levels of VEGF (Vascular Endothelial Growth Factor), which is the main regulator of this process. In vitro experiments showed that VEGF stimulates mitosis of endothelial cells and their migration. VEGF may be also secreted by tumour cells and it acts in an autocrine manner to promote cell growth \[[@CR33], [@CR34]\]. In our study VEGF levels were significantly higher in patients with OSCC than in healthy controls both in serum and saliva. Similar results were obtained by other researchers \[[@CR34]--[@CR36]\], but there are also studies which demonstrated elevated salivary and serum levels of VEGF in OSCC patients without finding significant differences \[[@CR37], [@CR38]\]. Congruent outcomes were obtained by researchers who assessed the level of VEGF in tissue samples \[[@CR39]\]. In a study carried out by Upile et al. \[[@CR34]\] a direct correlation between T stage and N stage of the patients with OSCC and VEGF levels were found. Our research revealed a significant correlation between VEGF salivary and serum levels and clinicopathological features such as histology grading and T stage. These relationships are so important that some researchers suggest the possibility of using this protein as a tumour marker \[[@CR35], [@CR36]\].

As it is well documented, the main risk factors for head and neck cancer are tobacco, alcohol abuse and betel quid chewing but some types of head and neck SCC are linked to viral infections such as HPV and EBV.

HPV infection has been recognized as a necessary but not the only one cause of certain types of human cancers because cancer eventually develops only in a small group of individuals infected with HPV. Other factors are, therefore, necessary for malignant transformation of HPV-infected cells \[[@CR21], [@CR40]\]. Chronic inflammation by HPV with an inadequate host immune response may provide a potential for tumor formation. According to Chuang et al. \[[@CR41]\], the development of HPV(+) OSCC is associated with IL-10 expression. These researchers demonstrated that HPV(+) patients with OSCC had higher IL-10 mRNA levels than HPV(−) patients. They also suggested that IL-10 may suppress T-cell immunity, which results in a persistent HPV infection. The correlation between higher levels of IL-10 in the group of patients with OSCC and the presence of HPV was also observed in our study. Moreover, the increase in the expression of IL-10 gene in people infected with HPV was demonstrated in the case of other types of tumours, such as cervical cancer \[[@CR42]\].

VEGF is also a cytokine investigated toward its prognostic value in patients infected with HPV. Jo et al. \[[@CR43]\] observed a significant increase in VEGF mRNA levels in HPV(+) tumours. Other researchers \[[@CR44]\], however, did not obtain similar results. The present study also did not reveal such a correlation between VEGF and HPV status.

Many researchers found that HPV(+) and HPV(−) OSCC are two distinct forms of the disease. In general, HPV(+) cancer patients are younger, have a much better prognosis than HPV(−) \[[@CR39], [@CR41], [@CR43], [@CR45]\]. According to Chen et al. \[[@CR45]\], high expression of IL-10 predicts a poor prognosis in OSCC. Chuang et al. \[[@CR41]\] based on their research indicated that IL-10 mRNA expression levels may independently predict the survival and recurrence rates in patients with HPV(+) OSCC, but not in those with HPV(−) cancer.

Shi et al. \[[@CR46]\] suggest that two DNA viruses, Epstein-Barr virus (EBV) and human papillomavirus (HPV), are associated with 38 % of all virus-associated cancers and the probability of one patient infected with two distinct types of viruses is increasing. During primary infection EBV infects oral epithelial cells and B lymphocytes. Like other herpesviruses, EBV has a productive lytic cycle and a latent form. Latently infected B cells can occasionally be stimulated to reactivate EBV \[[@CR47]\]. Activation of the lytic phase or reactivation from latency is a key to virus transmission. Most diseases related to EBV infection are associated with the latent form of infection. Some of early products that further act as transactivators of the viral lytic phase are BZLF1 and BRLF1. BZLF1 plays important role in attenuating the host immune response to lytic viral infection \[[@CR48]\]. In the lytic infection BZLF1 inhibits the activity of the promoter for the gene encoding TNF-α receptor and decreased expression of the TNFR1 protein \[[@CR49]\]. Besides, it is unable to induce cellular apoptosis. TNF-α activates expression of various important inflammatory genes and it induces apoptosis.

BZLF1 stimulates expression of both TGF-β and IL-10 \[[@CR49]\]. Epstein-Barr virus late gene BCRF1 is very similar to the human IL-10 gene (84 % homology in amino acids sequence). This late viral gene product vIl-10 (BCLF1) plays an important role for the protection of the virus from the host immune response. The results of this process, namely the infection with EBV, may develop tumour diseases.

Many questions are unclear and will need to be answered by future studies. All the above-mentioned cytokines and growth factors act on the tumour growth. Some of them were definitely studied and explained long ago, some are constantly being investigated. Explaining the reasons for this influence is very difficult because many cytokines interact in various ways on cells, often in an antagonistic manner, depending on the concentration. There is no doubt that viruses which have the ability to connect with the genetic material of the host cells can significantly disrupt gene expression for cytokines and growth factors.

It has been confirmed in numerous studies that HPV and EBV have the ability to cause various cancers, but there is a lack of studies which determine variability in the levels of cytokines in patients with OSCC with EBV infections.

Conclusions {#Sec13}
===========

Our results clearly indicate increased levels of IL-10, TNF-α, TGF-β and VEGF both in serum and saliva and they suggest that these cytokines may constitute valuable tools in diagnosis, treatment and prognosis in cancer disease. However, further research is still required to prove the role and mode of action of potential biomarkers.
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